Substantial efforts have been to design drug carriers for targeted drug delivery to tumor sites in order to spare the normal tissue from the hazardous effects of chemotherapeutic agents and achieve better therapeutic efficacy [2, 4, 37, 39]. One promising approach to reduce chemotoxicity would be to conjugate or encapsulate these potent drugs into nanometer (10–400) sized particles and trigger their release at tumor sites [12, 13, 20]. However, nanoparticulates frequently accumulate in the liver, which leads to high local concentrations of these toxic drugs. This accumulation reduces delivery of the appropriate dose of drugs to the site of action and can generate hepatotoxicity.
The aim of this project is to design a nano drug carrier that extends plasma circulation, permits greater tumor accumulation, and reduces hepatotoxicity, which is based on the enhanced permeability and retention effect. To achieve this goal, a novel approach to produce N-glycosylated peptide nanoparticles has been explored.
Elastin-like polypeptides are repeated pentameric peptides VPG XG exhibiting a characteristic inverse phase transition temperature Tt, above which they form aggregates from a monodisperse solution. It is hypothesized that on triggering the phase transition of an N-glycosylated-ELP-drug conjugate, it will form nanostructures with insoluble ELP-drug at the core shielded with soluble N-linked carbohydrates. For this purpose, a library of ELP VPGAG consisting of 6, 12, 24, 48, 96, 192 pentamers was constructed. This was followed by biosynthesis of several constructs comprising of ELP A96 and A192 with Endoplasmic Reticulum Signal and N-glycosylation sequences using recombinant DNA technology.
Expression of these constructs and GFP plasmid was optimized into mammalian HEK 293 cells using L-PEI as transfection agent. Successful expression of GFP protein alone and its co-transfection with N-glycosylation + ELP A 192 and A96 sequences was evaluated using fluorescence microscopy. However, N-glycosylated ELP or ELP (A192 and A96) did not exhibit any obvious phase transition in the medium collected before and after HEK293 cell lysis. Thus, expression of N-glycosylated ELP or ELP protein could not be determined.
|Advisor:||MacKay, Andrew J.|
|Commitee:||Hamm-Alvarez, Sarah, Okamoto, Curtis|
|School:||University of Southern California|
|School Location:||United States -- California|
|Source:||MAI 49/01M, Masters Abstracts International|
Copyright in each Dissertation and Thesis is retained by the author. All Rights Reserved
The supplemental file or files you are about to download were provided to ProQuest by the author as part of a
dissertation or thesis. The supplemental files are provided "AS IS" without warranty. ProQuest is not responsible for the
content, format or impact on the supplemental file(s) on our system. in some cases, the file type may be unknown or
may be a .exe file. We recommend caution as you open such files.
Copyright of the original materials contained in the supplemental file is retained by the author and your access to the
supplemental files is subject to the ProQuest Terms and Conditions of use.
Depending on the size of the file(s) you are downloading, the system may take some time to download them. Please be